Authors
Latest:
Can AI Accelerate Clinical Review at FDA?With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Latest:
The Strategies Behind Bringing a Novel Therapy to Market SuccessfullyKey areas may offer useful strategies for introducing innovative products to market.
Latest:
The Price of Prescriptions: Getting it RightDrug companies face new hurdles in a rapidly changing marketplace. How do they finance new drug development amid the uncertainty?
Latest:
Patient Treatment & Travel: The Need for Stepped-Up SupportDesigning an effective travel and lodging patient hub program in pharma.
Latest:
Transforming Healthcare: Beyond Buzzwords to Purposeful ChangeFor a growth mindset to truly take hold, leaders must create space for those possibilities to thrive.
Latest:
Rethinking Market Strategy within a Patient-Centric EraA panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.
Latest:
Is Community the Next Frontier for Cell and Gene Therapy?Both community and academic delivery models play essential and complementary roles in expanding CGT access.
Latest:
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global InvestmentA look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Latest:
Industry Predictions For 2023Top industry experts weigh in on what the new year holds for the pharma industry.
Latest:
How Bringing Pharmacovigilance In-House Drives Better Oversight and Faster Data AnalysisFor companies in the life science industry, managing their processes in house on their own platforms proved beneficial.
Latest:
What Would Happen if Foreign Markets Became Friendlier to Innovation than the US?The MFN executive order may result in the US losing its place as the friendliest market for innovation.
Latest:
Technology Overload: Addressing Site Challenges of Digital TrialsWebinar Date/Time: Wednesday, August 30, 2023 at 11am EDT
Latest:
3 Reasons US Payers Will Make 2021 a Banner Year for BiosimilarsFollowing a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.
Latest:
Measuring Pharma’s Wider MandateEspecially critical amid the continuing global pandemic, key metrics are laid out to help life sciences companies define, measure, and effectively communicate sustainability practices and progress—and build foundations for long-term business value.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
Using AI to Predict Launch SuccessHow to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.
Latest:
Strategies for Success in an Evolving Commercialization LandscapeA phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.
Latest:
Embracing Digital Education During COVID-19 CrisisAs the world of medicine continues to face the impact of the COVID-19 pandemic, clinicians are increasingly looking to digital solutions, including continuing medical education (CME), to stay current on the latest developments in their field.
Latest:
Advancing Health Innovation in 2022: Where Should We Focus?What can both public and private sector stakeholders learn from current trends to accelerate innovation around the COVID-19 pandemic and other emerging global health threats, including antimicrobial resistance?
Latest:
How Digital Twins Drive Sustainability in Clinical Supply PlanningEmerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.
Latest:
NFTs: What This New Kid on the Blockchain Means for HealthcareThere has been a push to implement NFTs, or non-fungible tokens, across many verticals, but there is still much to learn about their potential uses in healthcare and its brands.
Latest:
How GxP Leaders Can Assess and Approach a Company’s Quality CultureUsing the interview process to ensure high organizational standards.
Latest:
Securing the Safety Net in Drug Access and SupportA look at the intersection of rigorous compliance and ethical behavior: independent, charitable patient assistance foundations.
Latest:
Next-level Efficacy: MounjaroDual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.
Latest:
Top Five Trends in Life Sciences Compliance for 2022Patient protection and social influence among trends to look out for as calendar turns.
Latest:
FDA Grants Breakthrough Therapy Designation to Merck, Daiichi Sankyo’s R-DXd for Platinum-Resistant Ovarian CancerR-DXd has previously shown promising clinical results in platinum-resistant ovarian, peritoneal, and fallopian tube cancers.
Latest:
Virtual Medical Affairs Audits: A Viable AlternativeVirtual audits proving to be beneficial post-COVID despite continuing challenges.
